AZIENDA SOCIO SANITARIA TERRITORIALE PAPA GIOVANNI XXIII

Their core work

ASST Papa Giovanni XXIII is a large Italian public hospital in Bergamo that participates in European clinical research as a trial site — providing patient access, clinical expertise, and real-world medical infrastructure for research consortia. In H2020, they contributed to two randomised or phase-level clinical trials in fundamentally different specialties: a rare liver disease gene therapy program and a cardiac emergency intervention study. Their value to research consortia is the combination of a high-volume tertiary care center with specialist departments capable of running complex interventional trials simultaneously. They are consumers of research protocols and generators of clinical data, not developers of laboratory technology.

What they specialise in

How they've shifted over time

Both H2020 projects began in 2018, so there is no true chronological evolution to observe — ASST Papa Giovanni XXIII entered EU research simultaneously in two separate clinical domains. The analytical split between early and recent keywords reflects the two parallel specialties rather than a strategic shift over time. What this does reveal is that the hospital is not narrowly focused: it engages in rare metabolic disease research at one end and acute cardiac intervention at the other, suggesting broad departmental reach rather than a single research niche.

With only two projects both starting in 2018 and no coordinator roles taken, the hospital appears to be an occasional clinical partner rather than an institution building a sustained EU research program — future collaborations are most likely in high-acuity clinical trial niches where patient access and specialist ICU capacity are the differentiating factor.

How they like to work

ASST Papa Giovanni XXIII has participated exclusively as a consortium partner, never leading a project, which is typical for public hospitals whose primary contribution is clinical access rather than research design. Both projects placed them inside large multi-country consortia — 28 unique partners across 11 countries across just two projects — suggesting they join well-established research networks rather than building bilateral relationships. Working with them means gaining access to a high-volume northern Italian hospital with specialist departments, not a research management team capable of driving project coordination.

Across two projects, ASST has connected with 28 distinct consortium partners spanning 11 countries, which is a broad European footprint for an organization with such limited project volume. This suggests they were placed into large, well-funded international clinical trial networks rather than forming an organic partnership base of their own.

What sets them apart

Papa Giovanni XXIII is one of the largest hospitals in the Lombardy region and gained international recognition during the COVID-19 pandemic as a front-line tertiary care center — its clinical capacity and patient throughput are substantial. For consortium builders, the differentiator is access to a high-volume Italian clinical site with demonstrated capability in both rare disease trials and acute cardiac intervention simultaneously. Compared to university hospitals, it offers a more operational, patient-facing profile with real-world treatment volumes that matter for clinical endpoints.

Highlights from their portfolio

• EURO SHOCK
  The larger-funded of the two projects (€252,375), addressing a high-mortality emergency cardiology scenario with ECMO — a technically demanding intervention that few hospitals can deliver at trial quality.
• CureCN
  A gene therapy clinical trial for an ultra-rare liver disease (Crigler-Najjar Syndrome affects roughly 1 in 1 million people), positioning ASST as a site capable of enrolling and managing patients in first-in-class gene therapy programs.